CytomX Therapeutics, Inc. (CTMX): Nasdaq/NYSE listing notice — CytomX receives Nasdaq delisting notice for bid price non-compliance

CytomX Therapeutics, Inc.

Nasdaq notified CytomX on Feb 24, 2025 that common stock bid price stayed below $1.00 for 30 consecutive business days through Feb 21, 2025.
Company has 180 calendar days, until August 25, 2025, to regain compliance by closing at $1.00 for 10 consecutive business days.
If not cured by the deadline, CytomX may transfer to Nasdaq Capital Market for an additional 180-day compliance period.
Company will monitor bid price and consider options, but there is no assurance of regaining compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

CytomX Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

5 and February 21, 2025 the Company’s common stock, $0.00001 par value per share (the “Common Stock”), had not maintained a minimum bid price of $1.00 per share, required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Notice has no immediate effect on the listing of the Company’s common stock.

View on SEC.gov

Browse all listing & compliance notices →

CytomX Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-036794

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.